Released Mar 28, 2024, after the close
10-K filed Mar 28, 2024, 88 days after period end · 0001390478-24-000004
Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$0.00$0.00 derived— vs Q4 2022no prior Q3 2023 on file
Net Income-$8.14M-$8.14M derivedN/M vs Q4 2022N/M vs Q3 2023
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$8,177,000N/M
Operating Cash Flowderived-$4,825,000N/M
What the release said
The release
Same quarter
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $1.90M |
| Net Income | -$8.14M | -$9.12M | -$6.60M | -$3.72M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR